ERC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Endocrine-Related Cancer 13 (2) 401-413    DOI: 10.1677/erc.1.01182
Copyright © 2006 by the Society for Endocrinology.
This Article
Right arrow Abstract Freely available
Right arrow Free Full Text
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Weng, J-R
Right arrow Articles by Chen, C-S
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Weng, J-R
Right arrow Articles by Chen, C-S



This article has been cited by other articles:


Home page
 Mol. Pharmacol.Home page
S. Wei, L.-F. Lin, C.-C. Yang, Y.-C. Wang, G.-D. Chang, H. Chen, and C.-S. Chen
Thiazolidinediones Modulate the Expression of beta-Catenin and Other Cell-Cycle Regulatory Proteins by Targeting the F-Box Proteins of Skp1-Cul1-F-box Protein E3 Ubiquitin Ligase Independently of Peroxisome Proliferator-Activated Receptor {gamma}
Mol. Pharmacol., September 1, 2007; 72(3): 725 - 733.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
H. Hasegawa, Y. Yamada, K. Komiyama, M. Hayashi, M. Ishibashi, T. Sunazuka, T. Izuhara, K. Sugahara, K. Tsuruda, M. Masuda, et al.
A novel natural compound, a cycloanthranilylproline derivative (Fuligocandin B), sensitizes leukemia cells to apoptosis induced by tumor necrosis factor related apoptosis-inducing ligand (TRAIL) through 15-deoxy-{Delta}12, 14 prostaglandin J2 production
Blood, September 1, 2007; 110(5): 1664 - 1674.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
R. Coras, A. Holsken, S. Seufert, J. Hauke, I. Y. Eyupoglu, M. Reichel, C. Trankle, F. A. Siebzehnrubl, R. Buslei, I. Blumcke, et al.
The peroxisome proliferator-activated receptor-{gamma} agonist troglitazone inhibits transforming growth factor-{beta}-mediated glioma cell migration and brain invasion
Mol. Cancer Ther., June 1, 2007; 6(6): 1745 - 1754.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
E. A. Wohlfert, F. C. Nichols, E. Nevius, and R. B. Clark
Peroxisome Proliferator-Activated Receptor {gamma} (PPAR{gamma}) and Immunoregulation: Enhancement of Regulatory T Cells through PPAR{gamma}-Dependent and -Independent Mechanisms
J. Immunol., April 1, 2007; 178(7): 4129 - 4135.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Free Full Text
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Weng, J-R
Right arrow Articles by Chen, C-S
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Weng, J-R
Right arrow Articles by Chen, C-S